From Yahoo Finance: 2025-04-10 05:40:00

Tempest Therapeutics seeks buyer or partner to advance liver cancer drug, amezalpat, for late-stage testing. Ended 2024 with $30 million in cash, not enough for Phase 3 trial. Biotech sector funding decline hinders additional funding efforts. Completed one-for-13 share consolidation amid global tariff imposition, avoided stock market volatility through reverse merger strategy. Amezalpat reduced risk of death by 35% when combined with Roche drugs Tecentriq and Avastin in Phase 2 trial for hepatocellular carcinoma. Combination also extended median survival to 21 months compared to 15 months for Roche drugs alone.

Read more: Tempest seeks strategic alternatives as cash runs out for Phase 3 trial